immunotherapy based biotechs into 2012

Interesting article here:

http://seekingalpha.com/article/379931-a-roadmap-for-immunotherapy-success-in-oncology

Plenty of action coming this year by the look.

As soon as Prima post more positive trial results the big boys will be sniffing around. Collaborative development may be inevitable and the possible consequences predictable:

"The most promising companies are merged out of existence when a co-development agreement with a larger biotech or pharmaceutical company suddenly becomes more than that (e.g. AMGN's BioVex acquisition). Fortunes are made and the acquired compound lives
on to be marketed and distributed by stronger hands. This is the likely path for the most promising companies focused on immunotherapy."

Looks like there's plenty of competition for the investors dollar too. Wonder how a small upstart from the antipodes will fare?

Good comments re DNDN can't hurt either.

Looking pretty positive for the sector in '12.
GLAH